Geptanolimab for Patients With Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Activity and Safety of Geptanolimab (GB226) for Patients With Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-Arm Study
Clin. Cancer Res 2020 Oct 12;[EPub Ahead of Print], Y Shi, Q Cai, Y Jiang, G Huang, M Bi, B Wang, Y Zhou, G Wang, H Ying, Z Tao, C Shi, Q Guo, C GaoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.